

Special Issue

COVID Vaccines: Design, Development, and Immune Response Studies

Message from the Guest Editors

COVID-19 vaccines have represented an unprecedented effort to contain a pandemic. Developed at record time, they have saved millions of lives over the past couple of years. Nevertheless, there is still room for improvement at different fronts, ranging from the elicitation of mucosal immunity and the prevention of transmission to the ability to elicit greater immune responses in immunocompromised patients. While it is currently not clear whether yearly boosts will continue to be required, multivalent vaccines based on updated versions of the Spike protein are under development, as well as vaccines based on SARS-CoV-2 antigens other than Spike, and combo vaccines with flu and pneumococcus. In this Special Issues, we welcome original research and systematic reviews on vaccine design, immune responses, and different boosting protocols.

Guest Editors

Dr. Fabrizio Maggi

Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy

Dr. Licia Bordi

Laboratory of Virology, National Institute for Infectious Diseases "L. Spallanzani", Via Portuense 292, 00149 Rome, Italy

Deadline for manuscript submissions

closed (31 May 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/148531

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).